最新消息分類研發臨床進展

漢康生技攜手 Aston Sci 展開策略合作　結合癌症疫苗與次世代免疫療法，探索創新聯合治療潛力 HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations

HanchorBio and Aston Sci today announced a strategic research collaboration to evaluate novel combination therapies joining HanchorBio's HCB101 macrophage-directed immunotherapy with Aston Sci's therapeutic cancer vaccine candidates.

10 月 22, 2026

漢康生技召開科學顧問委員會議　HCB101 臨床進展與 FDA 共識支持邁向全球註冊性臨床開發 HanchorBio Advances HCB101 Toward Global Registrational Development Following SAB Review and FDA Alignment

HanchorBio announced outcomes from its latest Scientific Advisory Board (SAB) meeting. Highlights included significant clinical progress for its lead asset, HCB101; alignment with the U.S. FDA on a registrational pathway in second-line gastric/ gastroesophageal junction (GC/GEJ) cancer; and continued expansion of the company’s research pipeline across oncology and immune-mediated diseases.

10 月 19, 2026

漢康生技擴大 HCB101 於台灣大腸直腸癌臨床開發二線治療初步數據顯示 ORR 達 50%、DCR 達 100% HanchorBio Expands HCB101 Colorectal Cancer Program in Taiwan as Early 2L CRC Data Show 50% ORR and 100% DCR

HanchorBio today announced that the first patient in Taiwan has been dosed in the colorectal cancer (CRC)-specific cohort of its global Phase 1b/2a HCB101-201 study (NCT06771622), expanding the Company’s global development program in second-line metastatic CRC.

10 月 14, 2026

漢康-KY向TFDA提交 HCB303 IND 申請　推進三特異性免疫療法全球臨床開發 HanchorBio Advances HCB303 Global Clinical Development with Taiwan TFDA IND Submission Following US FDA Clearance

HanchorBio announced the submission of an Investigational New Drug (IND) to the Taiwan Food and Drug Administration (TFDA) for HCB303.

10 月 08, 2026

漢康-KY宣布 HCB303 IND 獲美國 FDA 同意　新一代三特異性免疫療法邁入臨床開發 HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy

HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for HCB303. The clearance enables HanchorBio to initiate its Phase 1 first-in-human clinical trial.

10 月 03, 2026

漢康-KY第二屆技術研發日揭示全球成長策略與多元產品線布局 HanchorBio Outlines Global Growth Strategy and Multi-Asset Pipeline at Second Annual R&D Day

HanchorBio hosted its second R&D Day. The Company presented its evolution from a single-asset clinical validation model into a multi-asset, macrophage-directed immunotherapy platform with global commercial potential.

9 月 23, 2026

漢康生技五項臨床研究入選 CSCO 2026 HanchorBio to Present Five Clinical Abstracts at CSCO 2026

HanchorBio announced that five company-sponsored clinical abstracts have been accepted for presentation at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2026).

9 月 18, 2026

漢康生技攜手 InSilicoTrials 推進 HCB101 AI 驅動臨床開發 HanchorBio Partners with InSilicoTrials to Advance AI-Driven Clinical Development for HCB101

HanchorBio announced that it has entered into a strategic memorandum of understanding (MOU) and an initial statement of work with InSilicoTrials Technologies S.p.A.

9 月 16, 2026

漢康生技 HCB101 達成臨床開發里程碑　美FDA 同意單一病人擴大使用（恩慈使用） HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit

HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared its HCB101 Single-Patient Expanded Access Protocol (HCB101- EA-001) as “safe to proceed”.

9 月 09, 2026

漢康-KY向美國 FDA 提交 HCB303 IND 申請　第二款三特異性免疫療法邁向臨床開發 HanchorBio Files U.S. IND for Second Trispecific Immunotherapy, HCB303

HanchorBio announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for HCB303. Developed using HanchorBio’s proprietary FBDB™ platform, HCB303 is the Company’s second trispecific immunotherapy program to reach clinical development.

9 月 03, 2026